7.1 Malaria Management: Diagnostics, Uncomplicated & Severe Malaria Protocols

7.1 Malaria Management: Diagnostics, Uncomplicated & Severe Malaria Protocols

Quick Answer: Malaria remains the leading cause of outpatient attendance and child mortality across Ghana. Caused by protozoan parasites of the genus Plasmodium and transmitted by female Anopheles mosquitoes, it presents as either uncomplicated illness or life-threatening severe malaria. Under guidelines of Ghana's National Malaria Elimination Programme (NMEP, formerly the National Malaria Control Programme), universal parasitological confirmation via Giemsa microscopy or Rapid Diagnostic Tests (RDTs) is mandatory before therapy. First-line therapy for uncomplicated malaria consists of Artemisinin-based Combination Therapies (ACTs): Artemether-Lumefantrine (AL, taken with fatty food/milk), Artesunate-Amodiaquine (AA), or Dihydroartemisinin-Piperaquine (DHAP). Severe malaria—defined by impaired consciousness, severe anemia (Hb < 5 g/dL in children), respiratory distress, or hypoglycemia—is an acute medical emergency requiring immediate parenteral artesunate (2.4 mg/kg IV/IM; 3.0 mg/kg for children < 20 kg) administered at 0, 12, and 24 hours, alongside meticulous supportive nursing care.

---

Epidemiology & Plasmodium Species in Ghana

In Ghana, malaria transmission is perennial with marked seasonal intensification during and immediately following the rainy seasons. Transmission dynamics and clinical severity depend heavily on the infecting Plasmodium species:

1. Plasmodium falciparum (> 90% of cases): The predominant pathogen across all ecological zones of Ghana (forest, coastal savanna, northern savanna). It invades erythrocytes of all ages, produces high parasitemia, and uniquely expresses Plasmodium falciparum erythrocyte membrane protein 1 (PfEMP1). This surface ligand mediates cytoadherence to endothelial receptors (CD36, ICAM-1) and sequestration of parasitized red blood cells in deep microvascular beds, causing microcirculatory obstruction, cerebral malaria, and organ failure.
2. Plasmodium malariae (a minority of infections, often mixed with P. falciparum): Causes quartan malaria characterized by a 72-hour paroxysm cycle. It invades senescent erythrocytes, resulting in low-density parasitemia, chronic infection, and potential immune-complex glomerulonephritis (nephrotic syndrome).
3. Plasmodium ovale (uncommon): Causes benign tertian malaria with a 48-hour febrile cycle. Forms dormant hepatic stages (hypnozoites) capable of reactivating months to years later to cause clinical relapses. Relapse prevention requires terminal eradication of hypnozoites with primaquine after ruling out glucose-6-phosphate dehydrogenase (G6PD) deficiency.
4. Plasmodium vivax (extremely rare in Ghana): Rare in indigenous West African populations due to the widespread absence of the Duffy antigen (Duffy-negative blood phenotype, Fy[a-b-]), which serves as the obligate erythrocyte surface receptor for P. vivax merozoite invasion.

---

Plasmodium Life Cycle Fundamentals

A comprehensive understanding of the malaria life cycle is foundational for understanding pathogenesis, timing of symptoms, and pharmacological points of intervention:

                             THE PLASMODIUM LIFE CYCLE
                                         |
           +-----------------------------+-----------------------------+
           |                                                           |
   [EXO-ERYTHROCYTIC (HEPATIC) PHASE]                    [ERYTHROCYTIC (BLOOD) PHASE]
           |                                                           |
   Infected Female Anopheles                               Merozoites Invade RBCs
   Bites Human Host                                                    |
           |                                               Trophozoite (Ring Form)
   Sporozoites Injected into Bloodstream                               |
           |                                               Erythrocytic Schizont
   Invade Hepatocytes (< 60 minutes)                                   |
           |                                               RBC Rupture & Merozoite Release
   Hepatic Schizogony (6-14 days)                             (Triggers Febrile Paroxysm)
   (P. ovale: Hypnozoites = Latency)                                  |
           |                                          +----------------+----------------+
   Hepatic Schizont Ruptures                          |                                 |
   Releases Thousands of Merozoites          Asexual RBC Reinvasion            Gametocytogenesis
   into Systemic Circulation                                          (Taken up by Mosquito Vector)

• Exo-Erythrocytic (Hepatic) Schizogony: Female Anopheles mosquitoes inoculate motile sporozoites during a blood meal. Within 30 to 60 minutes, sporozoites enter hepatic parenchymal cells. Over 6 to 14 days, each sporozoite replicates asexually, generating a hepatic schizont containing 10,000 to 30,000 merozoites. This phase is asymptomatic and resistant to standard blood schizontocides. P. ovale can differentiate into dormant hypnozoites that hibernate in hepatocytes.
• Erythrocytic Schizogony: Ruptured hepatic schizonts release merozoites into the bloodstream, where they invade red blood cells. Inside the erythrocyte, the parasite develops through the ring-stage trophozoite, mature trophozoite, and multinucleated erythrocytic schizont. The schizont ruptures the erythrocyte, releasing 8 to 24 daughter merozoites, metabolic toxins, and hemozoin (malaria pigment).
• Febrile Paroxysm Dynamics: The synchronized rupture of erythrocytes releases hemozoin and parasite antigens, triggering alveolar macrophages and monocytes to release pyrogenic cytokines (TNF-alpha, IL-1, IL-6). This initiates the classic malarial paroxysm: cold stage (chills and intense rigors), hot stage (high fever up to 40-41 C, flushing, throbbing headache), and sweating stage (drenching diaphoresis with defervescence).
• Gametocytogenesis: A subpopulation of intra-erythrocytic parasites differentiates into sexual forms—macrogametocytes (female) and microgametocytes (male). Gametocytes cause no clinical pathology in the human host but are taken up by a biting female Anopheles mosquito to complete the sexual cycle (sporogony).

---

Diagnostic Testing: Microscopy vs. Rapid Diagnostic Tests (RDTs)

The Ghana NMEP strictly enforces the "T3" initiative: Test, Treat, and Track. Every suspected malaria case must undergo parasitological confirmation prior to antimalarial administration.

Microscopic Parasitemia Calculation

On a thick blood smear, parasitemia is quantified by counting the number of parasites against 200 white blood cells (WBCs), assuming a standard baseline WBC count of 8,000 cells/uL:

$\text{Parasites per } \mu\text{L} = \frac{\text{Number of Parasites Counted}}{\text{Number of WBCs Counted (e.g., 200)}} \times 8{,}000$

Alternatively, on a thin film, percentage parasitemia is calculated by counting parasitized red cells among 1,000 to 2,000 erythrocytes:

$\% \text{ Parasitemia} = \frac{\text{Number of Parasitized RBCs}}{\text{Total RBCs Counted}} \times 100$

WHO defines hyperparasitemia as P. falciparum parasitemia above 10%, a criterion for severe malaria; lower but rising densities still need close monitoring, especially in young children and non-immune patients.

---

Uncomplicated Malaria: Clinical Features & First-Line ACT Protocols

Uncomplicated malaria presents with non-specific constitutional features without evidence of vital organ dysfunction: high fever, rigors, headache, generalized arthralgia, myalgia, nausea, vomiting, anorexia, and mild abdominal discomfort. Physical examination may reveal mild pallor, splenomegaly, and warm, flushed skin.

Ghana NMEP First-Line Artemisinin-Based Combination Therapies (ACTs)

Artemisinin derivatives provide rapid parasite clearance (reducing parasite biomass by a factor of 10,000 per 48-hour asexual cycle), while the longer-acting partner drug eliminates residual parasites and prevents recrudescence.

1. Artemether-Lumefantrine (AL) [Coartem]:
   • Regimen: 6-dose regimen administered over 3 days (0h, 8h, 24h, 36h, 48h, and 60h).
   • Administration Rule: Lumefantrine is highly lipophilic; its absorption increases up to sixteen-fold when co-administered with fatty food, whole milk, or fatty soup. If the patient cannot eat solid food, breastmilk or whole milk must be provided.
   • Cautions: Not established for infants under 5 kg. For the first trimester of pregnancy, WHO (2022) now recommends artemether-lumefantrine; older Ghanaian case-management guidelines used oral quinine plus clindamycin, so follow the national guideline in force at your facility.
2. Artesunate-Amodiaquine (AA):
   • Regimen: Administered once daily for 3 consecutive days.
   • Considerations: Can cause adverse effects such as nausea, dizziness, asthenia, and amodiaquine-induced extrapyramidal reactions or neutropenia. Highly effective where lumefantrine resistance or adherence to high-fat diets is a concern.
3. Dihydroartemisinin-Piperaquine (DHAP):
   • Regimen: Administered once daily for 3 consecutive days.
   • Administration Rule: Must be taken on an empty stomach (at least 3 hours after a meal, with food withheld for 3 hours post-dose), as dietary lipids increase piperaquine bioavailability and can prolong the cardiac QTc interval.

[!IMPORTANT] Vomiting Protocol for Oral ACTs: If the patient vomits within 30 minutes of tablet ingestion, re-administer the entire scheduled dose. If vomiting occurs between 30 and 60 minutes, administer half of the scheduled dose. If persistent vomiting prevents oral retention, transition the patient immediately to parenteral therapy.

---

Severe and Complicated Malaria: Diagnostic Criteria

Severe malaria is almost exclusively caused by P. falciparum and represents a medical emergency with mortality exceeding 20% if untreated. According to WHO and NMEP definitions, severe malaria is diagnosed when asexual P. falciparum parasitemia is accompanied by one or more of the following clinical or laboratory features without an alternative cause:

---

Emergency Management: Parenteral Artesunate Protocol

Parenteral artesunate is the preferred first-line medicine for severe malaria in all age groups, including pregnant women in all trimesters, significantly reducing mortality compared to intravenous quinine.

Dosing Schedules

• Children weighing < 20 kg: 3.0 mg/kg per dose IV or IM.
• Children weighing >= 20 kg and Adults: 2.4 mg/kg per dose IV or IM.
• Administration Schedule:
  • Dose 1: At hour 0 (immediate presentation).
  • Dose 2: At hour 12.
  • Dose 3: At hour 24.
  • Subsequent Doses: Once daily (every 24 hours) until the patient can swallow and retain oral medication.

Strict Two-Step Reconstitution Technique

Artesunate powder is unstable in solution and must be reconstituted immediately before injection following a mandatory two-step procedure:

                    ARTESUNATE TWO-STEP RECONSTITUTION
                                    |
   +--------------------------------+--------------------------------+
   |                                                                 |
[STEP 1: ACTIVATION & DISSOLUTION]                [STEP 2: CLINICAL DILUTION]
   Ampoule of Artesunate Powder (60 mg)              Add Diluent to the 1 mL Activated Solution:
   + 1.0 mL of 5% Sodium Bicarbonate                 -
   Shake vigorously for 2-3 minutes                  - For IV Push (10 mg/mL): 
   -> Forms Sodium Artesunate                        Add 5.0 mL of 0.9% Normal Saline or 5% Dextrose
   (Solution MUST be crystal-clear)                  -
                                                     - For IM Injection (20 mg/mL): 
                                                     Add 2.0 mL of 0.9% Normal Saline or 5% Dextrose

• Step 1 (Dissolution): Take the 60 mg vial of artesunate powder and inject 1.0 mL of 5% sodium bicarbonate diluent (supplied with the vial). Shake vigorously for 2 to 3 minutes until the powder dissolves completely. This alkaline buffer hydrolyzes artesunate to water-soluble sodium artesunate. The solution must be transparent; if it remains cloudy or shows precipitate, it must be discarded.
• Step 2 (Dilution):
  • For Intravenous (IV) Administration: Add 5.0 mL of 0.9% Normal Saline or 5% Dextrose in Water to the 1.0 mL activated solution (total volume = 6.0 mL; concentration = 10 mg/mL). Administer as a slow IV push over 1 to 2 minutes.
  • For Intramuscular (IM) Administration: Add 2.0 mL of 0.9% Normal Saline or 5% Dextrose in Water to the 1.0 mL activated solution (total volume = 3.0 mL; concentration = 20 mg/mL). Administer into the anterior thigh or upper outer gluteal quadrant.

Transition to Oral Therapy

The patient must receive a minimum of three parenteral doses (spanning the first 24 hours). Once the patient regains full consciousness, stops vomiting, and can swallow, discontinue parenteral artesunate and initiate a full 3-day course of oral ACT (Artemether-Lumefantrine, Artesunate-Amodiaquine, or DHAP). Never rely on oral artesunate monotherapy.

---

Critical Supportive Nursing Care

Nurses play an indispensable role in monitoring, preventing secondary injury, and resuscitating patients with severe malaria.

1. Hypoglycemia Monitoring & Correction: Check blood glucose upon admission, every 2 to 4 hours in comatose patients, and immediately following any seizure episode. Hypoglycemia (< 2.2 mmol/L) in severe malaria can occur silently without autonomic diaphoresis or tachycardia. Treat immediately with an intravenous bolus of 5 mL/kg of 10% Dextrose in Water in pediatric patients (or 20–50 mL of 50% Dextrose diluted in adults), followed by a maintenance infusion containing 5% or 10% dextrose.
2. Seizure Management: Maintain airway patency, position the patient in the lateral recovery position, and administer oxygen. If generalized seizures occur, terminate promptly with slow IV Diazepam at 0.15 to 0.3 mg/kg (maximum 10 mg in adults) over 2 to 3 minutes, or administer rectal diazepam (0.5 mg/kg). If seizures persist beyond two doses, administer IV Phenobarbital loading dose (15–20 mg/kg).
3. Temperature Control: Maintain core temperature below 38.5 C using paracetamol suppositories or syrup, loose clothing, and lukewarm tepid sponging. Do not use cold water or alcohol rubs, which trigger cutaneous vasoconstriction and shivering.
4. Fluid Management & Balance: Maintain strict intake and output charting via an indwelling urinary catheter. Comatose patients with severe malaria are at high risk of both acute renal tubular necrosis from hypovolemia and lethal non-cardiogenic pulmonary edema from fluid overload. Titrate maintenance fluids cautiously to avoid fluid overload, targeting a minimum urine output of >= 1.0 mL/kg/h in children and >= 0.5 mL/kg/h in adults.

[!CAUTION] Delayed Post-Artesunate Hemolysis Warning: Patients treated with parenteral artesunate can develop delayed hemolytic anemia 1 to 3 weeks following successful therapy, particularly those with hyperparasitemia. Discharge education must warn patients to return immediately if they develop severe pallor, fatigue, dark urine, or jaundice within one month of discharge.